CO5560577A2 - Uso de bibn4096 en combinacion con otros farmacos antimigrañosos para el tratamiento de la migraña - Google Patents
Uso de bibn4096 en combinacion con otros farmacos antimigrañosos para el tratamiento de la migrañaInfo
- Publication number
- CO5560577A2 CO5560577A2 CO04012009A CO04012009A CO5560577A2 CO 5560577 A2 CO5560577 A2 CO 5560577A2 CO 04012009 A CO04012009 A CO 04012009A CO 04012009 A CO04012009 A CO 04012009A CO 5560577 A2 CO5560577 A2 CO 5560577A2
- Authority
- CO
- Colombia
- Prior art keywords
- migraine
- treatment
- bibn4096
- pharmacos
- antimigraine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
1.- La presente invención se refiere a un método de tratamiento o prevención de cefalea, migraña o cefaleas en racimo, método que comprende la co-administración de una cantidad terapéuticamente eficaz del compuesto A = 1-[N2-[3,5-Dibromo-N-[[4-(3,4-dihidro-2(1H)-oxoquinazolin-3-il)-1-piperidinil]carbonil]-D-tirosil]-L-lisil]-4- (4-piridiniI)-piperazina [BIBN4096BS] o una de sus sales fisiológicamente aceptables y una cantidad terapéuticamente eficaz de un segundo fármaco antimigrañoso activo, particularmente sumatriptán, zolmitriptán o dihidroergotamina o una de sus sales fisiológicamente aceptables, así como a las correspondientes composiciones farmacéuticas y su preparación.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10139410A DE10139410A1 (de) | 2001-08-17 | 2001-08-17 | Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5560577A2 true CO5560577A2 (es) | 2005-09-30 |
Family
ID=7695082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04012009A CO5560577A2 (es) | 2001-08-17 | 2004-02-12 | Uso de bibn4096 en combinacion con otros farmacos antimigrañosos para el tratamiento de la migraña |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1420790B1 (es) |
| JP (1) | JP2005503382A (es) |
| KR (1) | KR20040027892A (es) |
| CN (1) | CN1543347A (es) |
| AR (1) | AR036265A1 (es) |
| AT (1) | ATE304854T1 (es) |
| BR (1) | BR0211970A (es) |
| CA (1) | CA2454083A1 (es) |
| CO (1) | CO5560577A2 (es) |
| DE (2) | DE10139410A1 (es) |
| EA (1) | EA200400253A1 (es) |
| EC (1) | ECSP044979A (es) |
| ES (1) | ES2250733T3 (es) |
| HR (1) | HRP20040150A2 (es) |
| HU (1) | HUP0401484A3 (es) |
| IL (1) | IL159879A0 (es) |
| MX (1) | MXPA04001364A (es) |
| NO (1) | NO20041024D0 (es) |
| PL (1) | PL365482A1 (es) |
| UY (1) | UY27416A1 (es) |
| WO (1) | WO2003015787A1 (es) |
| ZA (1) | ZA200400313B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8465468B1 (en) | 2000-06-29 | 2013-06-18 | Becton, Dickinson And Company | Intradermal delivery of substances |
| DE10207026A1 (de) * | 2002-02-20 | 2003-08-28 | Boehringer Ingelheim Kg | Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung |
| EP1374870A1 (en) * | 2002-06-24 | 2004-01-02 | Rita Dobmeyer | Medication for the treatment or prevention of migraine |
| DE10314617A1 (de) * | 2003-04-01 | 2004-10-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung des Hydrochlorids der Wirkstoffbase 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin in Kombination mit Sumatriptan zur Behandlung von Migräne |
| DE10338399A1 (de) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver |
| DE10338403A1 (de) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum |
| DE10338407A1 (de) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin |
| DE10338402A1 (de) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum |
| US20050065094A1 (en) | 2003-09-05 | 2005-03-24 | Boehringer Ingelheim International Gmbh | Use of telmisartan for the prevention and treatment of vascular headache |
| WO2005102322A1 (de) * | 2004-04-20 | 2005-11-03 | Boehringer Ingelheim International Gmbh | Verwendung eines cgrp-antagonisten in kombination mit einem serotonin-wiederaufnahme-hemmer zur behandlung von migräne |
| US20050256182A1 (en) * | 2004-05-11 | 2005-11-17 | Sutter Diane E | Formulations of anti-pain agents and methods of using the same |
| DE102004063753A1 (de) * | 2004-12-29 | 2006-07-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne |
| CN102526031A (zh) * | 2010-12-27 | 2012-07-04 | 湖南九典制药有限公司 | 一种鼻腔内使用的舒马普坦药物组合物及其制备方法 |
| CN103385876B (zh) * | 2012-05-08 | 2016-01-13 | 四川滇虹医药开发有限公司 | 一种夫罗曲坦的药物组合物及其制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9712023A (pt) * | 1996-09-10 | 1999-08-31 | Thomae Gmbh Dr K | Aminoácidos derivados, medicamentos contendo esses compostos e processos para a sua preparação. |
| DE19937304C2 (de) * | 1999-08-10 | 2003-08-21 | Boehringer Ingelheim Pharma | Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen |
-
2001
- 2001-08-17 DE DE10139410A patent/DE10139410A1/de not_active Withdrawn
-
2002
- 2002-08-10 EA EA200400253A patent/EA200400253A1/ru unknown
- 2002-08-10 ES ES02794772T patent/ES2250733T3/es not_active Expired - Lifetime
- 2002-08-10 BR BR0211970-6A patent/BR0211970A/pt active Pending
- 2002-08-10 AT AT02794772T patent/ATE304854T1/de not_active IP Right Cessation
- 2002-08-10 MX MXPA04001364A patent/MXPA04001364A/es unknown
- 2002-08-10 EP EP02794772A patent/EP1420790B1/en not_active Expired - Lifetime
- 2002-08-10 WO PCT/EP2002/008993 patent/WO2003015787A1/en active IP Right Grant
- 2002-08-10 CA CA002454083A patent/CA2454083A1/en not_active Abandoned
- 2002-08-10 IL IL15987902A patent/IL159879A0/xx unknown
- 2002-08-10 CN CNA028161327A patent/CN1543347A/zh active Pending
- 2002-08-10 JP JP2003520746A patent/JP2005503382A/ja active Pending
- 2002-08-10 HU HU0401484A patent/HUP0401484A3/hu unknown
- 2002-08-10 PL PL02365482A patent/PL365482A1/xx not_active Application Discontinuation
- 2002-08-10 KR KR10-2004-7002356A patent/KR20040027892A/ko not_active Application Discontinuation
- 2002-08-10 DE DE60206289T patent/DE60206289T2/de not_active Expired - Fee Related
- 2002-08-14 UY UY27416A patent/UY27416A1/es not_active Application Discontinuation
- 2002-08-16 AR ARP020103101A patent/AR036265A1/es not_active Suspension/Interruption
-
2004
- 2004-01-15 ZA ZA200400313A patent/ZA200400313B/xx unknown
- 2004-02-12 CO CO04012009A patent/CO5560577A2/es not_active Application Discontinuation
- 2004-02-16 EC EC2004004979A patent/ECSP044979A/es unknown
- 2004-02-16 NO NO20041024A patent/NO20041024D0/no not_active Application Discontinuation
- 2004-02-16 HR HR20040150A patent/HRP20040150A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR0211970A (pt) | 2004-09-21 |
| CN1543347A (zh) | 2004-11-03 |
| HUP0401484A3 (en) | 2007-03-28 |
| HUP0401484A2 (hu) | 2004-12-28 |
| KR20040027892A (ko) | 2004-04-01 |
| EA200400253A1 (ru) | 2004-08-26 |
| WO2003015787A1 (en) | 2003-02-27 |
| PL365482A1 (en) | 2005-01-10 |
| ES2250733T3 (es) | 2006-04-16 |
| CA2454083A1 (en) | 2003-02-27 |
| ECSP044979A (es) | 2004-04-28 |
| IL159879A0 (en) | 2004-06-20 |
| MXPA04001364A (es) | 2004-05-27 |
| NO20041024D0 (no) | 2004-02-16 |
| EP1420790B1 (en) | 2005-09-21 |
| JP2005503382A (ja) | 2005-02-03 |
| DE60206289T2 (de) | 2006-06-08 |
| HRP20040150A2 (en) | 2004-06-30 |
| ATE304854T1 (de) | 2005-10-15 |
| UY27416A1 (es) | 2003-03-31 |
| DE10139410A1 (de) | 2003-02-27 |
| EP1420790A1 (en) | 2004-05-26 |
| DE60206289D1 (de) | 2006-02-02 |
| ZA200400313B (en) | 2004-11-01 |
| AR036265A1 (es) | 2004-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5560577A2 (es) | Uso de bibn4096 en combinacion con otros farmacos antimigrañosos para el tratamiento de la migraña | |
| ATE401874T1 (de) | Verabreichung von capsaicinoiden | |
| HK1080459A1 (en) | Novel pyrimidineamide derivatives and the use thereof | |
| DOP2005000039A (es) | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
| ECSP066327A (es) | Composición de fexofenadina y proceso para prepararla | |
| EA200602092A1 (ru) | Способ и композиция для лечения ринита | |
| ES2721899T3 (es) | Composiciones farmacéuticas que comprenden fentanilo para su administración intranasal | |
| AR038571A1 (es) | Procedimiento para la preparacion de un producto de inhalacion en polvo que contiene una sal del antagonista de cgrp, bibn4096 | |
| MA27731A1 (fr) | Combinaison comprenant paroxetine et 2-(s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-acide carboxylique [1- (r)-(3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide destinee au traitement de la depression et/ou de l'anxiete | |
| DE60102590T2 (de) | Darreichungsformen zur behandlung von oralen mykosen | |
| AR031679A1 (es) | Una composicion farmaceutica | |
| DE50109650D1 (de) | Topische behandlung bei der mastalgie | |
| AR049846A1 (es) | Preparaciones farmaceuticas de derivados de la piperazina | |
| AR043793A1 (es) | Uso del hidrocloruro de la base del principio activo 1-[n2-[3,5-didromo-n-[[4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1-piperidinil]-carbonil]-d-tirosil]-l-lisil]-4-(4-piperidin)-piperazina en combinacion con sumatriptano para el tratamiento de la migrana | |
| AR037496A1 (es) | Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables | |
| SE0302924D0 (sv) | Pharmaceutical composition having a cationic excipient | |
| ATE431147T1 (de) | Mittel zur behandlung des integrationsdysfunktionssyndroms | |
| MXPA04005033A (es) | Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes. | |
| AR038572A1 (es) | Producto de inhalacion en polvo que contiene el antagonista de cgrp, bibn4096, y procedimiento para su preparacion | |
| SE0303135D0 (sv) | Controlled food effect composition | |
| ATE331523T1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion | |
| SE0203817D0 (sv) | New composition | |
| AR030551A1 (es) | Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante | |
| BG106430A (en) | Liquid mucoadhesive pharmaceutical composition | |
| UA123395U (uk) | Фармацевтична композиція ністатину у формі оральної суспензії |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |